Picture map of Europe with pins indicating European capital cities

Open Access research with a European policy impact...

The Strathprints institutional repository is a digital archive of University of Strathclyde's Open Access research outputs. Strathprints provides access to thousands of Open Access research papers by Strathclyde researchers, including by researchers from the European Policies Research Centre (EPRC).

EPRC is a leading institute in Europe for comparative research on public policy, with a particular focus on regional development policies. Spanning 30 European countries, EPRC research programmes have a strong emphasis on applied research and knowledge exchange, including the provision of policy advice to EU institutions and national and sub-national government authorities throughout Europe.

Explore research outputs by the European Policies Research Centre...

Application of a novel method to estimate incidence of hepatitis C among injecting drug users in Scotland

Palmateer, N. and Allen, E. and Taylor, A. and Hutchinson, S. and Goldberg, D. (2011) Application of a novel method to estimate incidence of hepatitis C among injecting drug users in Scotland. Journal of Epidemiology and Community Health, 65 (Supple). A79-A79. ISSN 0143-005X

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

Prevalence of the hepatitis C virus (HCV) among injecting drug users (IDUs) in Scotland is high. Through an HCV Action Plan, the Scottish Government has invested significantly in harm reduction interventions with the goal of reducing HCV transmission among IDUs. In evaluating the effectiveness of interventions, estimates of the incidence, rather than the prevalence, of HCV are essential. The traditional approach to measuring incidence—follow-up of a cohort of uninfected individuals to measure seroconversion—can, however, be costly and suffer high participant attrition rates. We report the first large-scale, national application of a novel method designed to determine incidence of HCV using a cross-sectional design. During 2008–2009, IDUs were recruited from needle exchange services, completed an interviewer-administered questionnaire and provided a dried blood spot for anonymous HCV-antibody (anti-HCV) and HCV-RNA testing. Incident infections were defined as individuals who were anti-HCV negative and HCV-RNA positive. Prevalence of anti-HCV was 55% among the 2563 participants. Among anti-HCV negative respondents, twenty-one were HCV-RNA positive, yielding an incidence estimate of 12.1 per 100 person-years (corresponding to a viraemic pre-seroconversion window period of 51 days). Individuals currently receiving methadone had lower odds of incident infection (adjusted OR 0.15; 95% CI 0.035 to 0.68) relative to those on methadone in the previous 6 months (but not currently). This approach to measuring incidence will allow us to gauge the impact of preventive interventions associated with the HCV Action Plan.